

May 11, 2021



Moleculin Biotech to Present at the Q2 Virtual Investor Summit

Live video webcast with President and CEO, Walter Klemp, on Monday, May 17, 2021 at 12:30 PM ET

HOUSTON, May 11, 2021 /PRNewswire/ --[Moleculin Biotech, Inc.](#), (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that [Walter Klemp](#), President and Chief Executive Officer of Moleculin, will present at the [Q2 Virtual Investor Summit](#) on Monday, May 17th at 12:30 PM ET.



In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the [conference website](#).

A live [video webcast](#) will be accessible on the [Events](#) page in the [Investors](#) section of the Company's website (www.moleculin.com) and archived for 90 days following the event.


About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a next-generation anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit <http://www.moleculin.com>.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com

 View original content to download multimedia <http://www.prnewswire.com/news-releases/moleculin-biotech-to-present-at-the-q2-virtual-investor-summit-301288084.html>

SOURCE Moleculin Biotech, Inc.